Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2

被引:0
|
作者
M J L Ligtenberg
F B L Hogervorst
H W Willems
P J W Arts
G Brink
S Hageman
E A J Bosgoed
E Van der Looij
M A Rookus
P Devilee
E M A W Vos
G Wigbout
P M Struycken
F H Menko
E J Th Rutgers
E H Hoefsloot
E C M Mariman
H G Brunner
L J Van’t Veer
机构
[1] University Hospital Nijmegen,Department of Human Genetics
[2] University Hospital Nijmegen,Department of Pathology
[3] The Netherlands Cancer Institute,Department of Pathology and The Family Cancer Clinic
[4] Plesmanlaan 121,Department of Epidemiology
[5] The Netherlands Cancer Institute,Department of Human Genetics and Department of Pathology
[6] Plesmanlaan 121,Department of Clinical Genetics
[7] University of Leiden,undefined
[8] Family Cancer Clinic,undefined
[9] University Hospital Vrije Universiteit,undefined
来源
British Journal of Cancer | 1999年 / 79卷
关键词
breast cancer; ovarian cancer; bilateral breast cancer;
D O I
暂无
中图分类号
学科分类号
摘要
For families with a small number of cases of breast and/or ovarian cancer, limited data are available to predict the likelihood of genetic predisposition due to mutations in BRCA1 or BRCA2. In 104 families with three or more affected individuals (average 3.8) seeking counselling at family cancer clinics, mutation analysis was performed in the open reading frame of BRCA1 and BRCA2 by the protein truncation test and mutation-specific assays. In 31 of the 104 families tested, mutations were detected (30%). The majority of these mutations (25) occurred in BRCA1. Mutations were detected in 15 out of 25 families (60%) with both breast and ovarian cancer and in 16 out of 79 families (20%) with exclusively cases of breast cancer. Thus, an ovarian cancer case strongly predicted finding a mutation (P < 0.001). Within the group of small breast-cancer-only families, a bilateral breast cancer case or a unilateral breast cancer case diagnosed before age 40 independently predicted finding a BRCA1 or BRCA2 mutation (P = 0.005 and P = 0.02, respectively). Therefore, even small breast/ovarian cancer families with at least one case of ovarian cancer, bilateral breast cancer, or a case of breast cancer diagnosed before age 40, should be referred for mutation screening.
引用
收藏
页码:1475 / 1478
页数:3
相关论文
共 50 条
  • [31] Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan
    Steven Shoei-Lung Li
    H.-M. Tseng
    Tsui-Ping Yang
    Chia-Han Liu
    Shiuh-Jen Teng
    Hung-Wen Huang
    L.-M. Chen
    Hsiao-Wei Kao
    Jimmy H. Chen
    Jau-Neng Tseng
    Angela Chen
    Ming-Feng Hou
    Tsung-Jen Huang
    Hong-Tai Chang
    King-Tong Mok
    Juei-Hsiung Tsai
    Human Genetics, 1999, 104 : 201 - 204
  • [32] Breast cancer risk for Korean women with germline mutations in BRCA1 and BRCA2
    Park, Boyoung
    Dowty, James G.
    Ahn, Choonghyun
    Win, Aung K.
    Kim, Sung-Won
    Lee, Min Hyuk
    Lee, Jong Won
    Kang, Eunyoung
    Hopper, John L.
    Park, Sue K.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (03) : 659 - 665
  • [33] Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers
    Synowiec, Agnieszka
    Wcislo, Gabriel
    Bodnar, Lubomir
    Gasowska-Bodnar, Agnieszka
    Szczylik, Cezary
    GINEKOLOGIA POLSKA, 2014, 85 (05) : 377 - 381
  • [34] BRCA1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients
    Zhang, Yinmei
    Wu, Heming
    Gan, Caiyan
    Rao, Hui
    Wang, Qiuming
    Guo, Xueming
    BMC MEDICAL GENOMICS, 2024, 17 (01)
  • [35] BRCA1 and BRCA2 germline mutations in 85 Iranian breast cancer patients
    Fatemeh Keshavarzi
    Gholam Reza Javadi
    Sirous Zeinali
    Familial Cancer, 2012, 11 : 57 - 67
  • [36] BRCA1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients
    Yinmei Zhang
    Heming Wu
    Caiyan Gan
    Hui Rao
    Qiuming Wang
    Xueming Guo
    BMC Medical Genomics, 17
  • [37] Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer
    Ramus, Susan J.
    Harrington, Patricia A.
    Pye, Carole
    DiCioccio, Richard A.
    Cox, Mark J.
    Garlinghouse-Jones, Kim
    Oakley-Girvan, Ingrid
    Jacobs, Ian J.
    Hardy, Richard M.
    Whittemore, Alice S.
    Ponder, Bruce A. J.
    Piver, M. Steven
    Pharoah, Paul D. P.
    Gayther, Simon A.
    HUMAN MUTATION, 2007, 28 (12) : 1207 - 1215
  • [38] Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations
    Hansen, Thomas v.O.
    Jonson, Lars
    Steffensen, Ane Y.
    Andersen, Mette K.
    Kjaergaard, Susanne
    Gerdes, Anne-Marie
    Ejlertsen, Bent
    Nielsen, Finn C.
    FAMILIAL CANCER, 2011, 10 (02) : 207 - 212
  • [39] Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients
    Yunuo Zhang
    Heming Wu
    Zhikang Yu
    Liang Li
    Jinhong Zhang
    Xinhong Liang
    Qingyan Huang
    BMC Cancer, 22
  • [40] The patterns and spectrum of BRCA1 and BRCA2 mutations in Iranian breast and ovarian cancer patients
    Shayan Forghani
    Hamid Reza Mirzaee
    Hamid Rezvani
    Arman Forghani
    Fatemeh Mahdavi Sabet
    Ali Hojjat
    Mona Malekzadeh
    Atieh Akbari
    Sanaz Tabarestani
    Familial Cancer, 24 (2)